About Metaphore Pharmaceuticals
Metaphore leads the emerging pharmaceutical frontier with its introduction of SOD mimetics, aka superoxide dismutase mimetic (SODm), which mimic, supplement, and enhance the human body's enzyme activity. Methaphore's products can be administered orally or topically as well as made into an aerosol. The company was founded in 1998 by Garland Marshall. Drug maker ActivBiotics plans to acquire the company
Missing: Metaphore Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Metaphore Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Metaphore Pharmaceuticals Frequently Asked Questions (FAQ)
When was Metaphore Pharmaceuticals founded?
Metaphore Pharmaceuticals was founded in 1998.
Where is Metaphore Pharmaceuticals's headquarters?
Metaphore Pharmaceuticals's headquarters is located at One Bridge Plaza, Fort Lee.
What is Metaphore Pharmaceuticals's latest funding round?
Metaphore Pharmaceuticals's latest funding round is Acquired.
How much did Metaphore Pharmaceuticals raise?
Metaphore Pharmaceuticals raised a total of $90.4M.
Who are the investors of Metaphore Pharmaceuticals?
Investors of Metaphore Pharmaceuticals include ActivBiotics, Advent Venture Partners, Prolog Ventures, Merrill, Lumira Ventures and 7 more.
Who are Metaphore Pharmaceuticals's competitors?
Competitors of Metaphore Pharmaceuticals include iPierian, Akebia Therapeutics, Omthera Pharmaceuticals, Combinent BioMedical Systems, Link Medicine and 12 more.
Compare Metaphore Pharmaceuticals to Competitors
ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Bridge Pharmaceutical aims to "bridge the gap" between the U.S. and Asia drug industries by transferring top FDA-compliant development technology to Asia.
InnoZen, Inc. discovers, develops, and markets, or out licenses, over-the-counter (OTC) health products that fulfill unmet consumer need. InnoZen developed a oral strip to deliver drug active ingredients. This technology is currently being used in new Chloraseptic' Relief Strips' and has many potential applications in both the human and veterinary markets.
Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.
Palkion, Inc. is a private early stage company developing oral drugs to treat anemia based on the discovery and development of compounds that inhibit prolyl hydroxylase enzymes.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.